Study of the multitarget mechanism of Astragalus (HUANGQI) in the treatment of Alzheimer’s disease based on network pharmacology and molecular docking technology

IF 3.9 3区医学 Q1 MEDICAL LABORATORY TECHNOLOGY

Pharmaceutical Biology Pub Date : 2024-07-27 DOI:10.1080/13880209.2024.2382962

Feng Lv, Mei Sun, Chunmeng Qin, Dan Du, Xiangru Zheng, Wenjun Li

引用次数: 0

Abstract

In China, HUANGQI is widely used for the treatment of Alzheimer’s disease (AD). However, a comprehensive understanding of its mechanism of anti-AD effects is lacking.To explore the active ingredien...

查看原文本刊更多论文

基于网络药理学和分子对接技术的黄芪治疗阿尔茨海默病的多靶点机制研究

在中国，黄芪被广泛用于治疗阿尔茨海默病（AD）。为了探索黄芪的有效成分，我们对黄芪进行了深入研究。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Pharmaceutical Biology 医学-药学

CiteScore

6.70

自引率

2.60%

发文量

191

审稿时长

1 months

期刊介绍： Pharmaceutical Biology will publish manuscripts describing the discovery, methods for discovery, description, analysis characterization, and production/isolation (including sources and surveys) of biologically-active chemicals or other substances, drugs, pharmaceutical products, or preparations utilized in systems of traditional medicine. Topics may generally encompass any facet of natural product research related to pharmaceutical biology. Papers dealing with agents or topics related to natural product drugs are also appropriate (e.g., semi-synthetic derivatives). Manuscripts will be published as reviews, perspectives, regular research articles, and short communications. The primary criteria for acceptance and publication are scientific rigor and potential to advance the field.